# Cormorant Asset Management, LP: Form 13F holdings

An institutional investment manager in BOSTON, MA. SEC CIK 1583977.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $1.95bn
- Positions: 50 (50 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1583977/000158397726000007/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [PRAXIS PRECISION MEDICINES I (PRAX)](/companies/prax.md) | COM NEW | $214.3m | 11.0% | 640,000 |  | Reduced −245,500 |
| [BRIDGEBIO ONCOLOGY THERAPEUT (BBOT)](/companies/bbot.md) | COM NEW | $136.2m | 7.0% | 17,878,594 |  | Unchanged |
| [PARABILIS MEDICINES INC (PBLS)](/companies/pbls.md) | COM | $126.3m | 6.5% | 4,615,612 |  | New +4,615,612 |
| [RAPPORT THERAPEUTICS INC (RAPP)](/companies/rapp.md) | COM | $110.7m | 5.7% | 2,657,521 |  | Reduced −300,000 |
| [ERASCA INC (ERAS)](/companies/eras.md) | COM | $109.9m | 5.6% | 6,000,000 |  | Added +200,000 |
| [EDGEWISE THERAPEUTICS INC (EWTX)](/companies/ewtx.md) | COM | $102.0m | 5.2% | 2,510,000 |  | Reduced −750,000 |
| [EYEPOINT INC (EYPT)](/companies/eypt.md) | COM NEW | $100.1m | 5.1% | 7,000,000 |  | Reduced −1,265,000 |
| [ALUMIS INC (ALMS)](/companies/alms.md) | COM | $92.5m | 4.7% | 3,285,596 |  | Reduced −663,645 |
| [ABIVAX SA (ABVX)](/companies/abvx.md) | SPONSORED ADS | $90.0m | 4.6% | 675,000 |  | Reduced −85,000 |
| [DIANTHUS THERAPEUTICS INC (DNTH)](/companies/dnth.md) | COM | $73.1m | 3.7% | 750,000 |  | Reduced −200,000 |
| [BRIGHT MINDS BIOSCIENCES INC (DRUG)](/companies/drug.md) | COM NEW | $63.2m | 3.2% | 900,000 |  | Reduced −159,331 |
| [MOONLAKE IMMUNOTHERAPEUTICS (MLTX)](/companies/mltx.md) | CLASS A ORD | $62.4m | 3.2% | 3,205,433 |  | Reduced −1,275,000 |
| [BIOAGE LABS INC (BIOA)](/companies/bioa.md) | COM | $58.6m | 3.0% | 2,390,605 |  | Reduced −500,000 |
| [ORUKA THERAPEUTICS INC (ORKA)](/companies/orka.md) | COM | $50.8m | 2.6% | 533,340 |  | Unchanged |
| [ADLAI NORTYE LTD (ANL)](/companies/anl.md) | SPONSORED ADS | $45.7m | 2.3% | 3,978,229 |  | Added +1,080,372 |
| [BRIDGEBIO PHARMA INC (BBIO)](/companies/bbio.md) | COM | $41.0m | 2.1% | 550,000 |  | Reduced −300,000 |
| [TANGO THERAPEUTICS INC (TNGX)](/companies/tngx.md) | COM | $40.6m | 2.1% | 1,300,000 |  | Reduced −125,000 |
| BIOHAVEN LTD | COM | $38.8m | 2.0% | 2,610,000 |  | Added +850,000 |
| [AGOMAB THERAPEUTICS NV (AGMB)](/companies/agmb.md) | SPONSORED ADS | $32.0m | 1.6% | 2,465,348 |  | Unchanged |
| [MBX BIOSCIENCES INC (MBX)](/companies/mbx.md) | COM | $30.4m | 1.6% | 550,000 |  | Reduced −570,000 |
| [CLIMB BIO INC (CLYM)](/companies/clym.md) | COM | $27.5m | 1.4% | 2,106,000 |  | New +2,106,000 |
| [OLEMA PHARMACEUTICALS INC (OLMA)](/companies/olma.md) | COM | $26.9m | 1.4% | 2,150,000 |  | Reduced −1,750,000 |
| DAMORA THERAPEUTICS INC | COM | $26.0m | 1.3% | 1,000,000 |  | Reduced −525,000 |
| PHARVARIS N V | COM | $25.9m | 1.3% | 750,000 |  | Reduced −250,000 |
| [CORBUS PHARMACEUTICALS HLDGS (CRBP)](/companies/crbp.md) | COM NEW | $22.0m | 1.1% | 2,344,971 |  | Unchanged |
| [SPYRE THERAPEUTICS INC (SYRE)](/companies/syre.md) | COM NEW | $20.0m | 1.0% | 225,000 |  | New +225,000 |
| [DEFINIUM THERAPEUTICS INC (DFTX)](/companies/dftx.md) | COM SHS | $18.8m | 1.0% | 400,000 |  | New +400,000 |
| NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | $16.9m | 0.9% | 500,000 |  | Reduced −450,000 |
| ROIVANT SCIENCES LTD | SHS | $16.8m | 0.9% | 475,000 |  | Reduced −275,000 |
| [CABALETTA BIO INC (CABA)](/companies/caba.md) | COM | $15.6m | 0.8% | 5,000,000 |  | Reduced −500,000 |
| HELIX ACQUISITION CORP III | USD CL A ORD SHS | $13.8m | 0.7% | 1,297,500 |  | Unchanged |
| ASCENDIS PHARMA A/S | ORD SHS | $13.3m | 0.7% | 50,000 |  | New +50,000 |
| [KAILERA THERAPEUTICS INC (KLRA)](/companies/klra.md) | COMMON STOCK | $12.1m | 0.6% | 550,000 |  | New +550,000 |
| [INSMED INC (INSM)](/companies/insm.md) | COM PAR $.01 | $8.0m | 0.4% | 75,000 |  | Reduced −115,000 |
| [FAETH THERAPEUTICS INC (FTH)](/companies/fth.md) | COM NEW | $7.7m | 0.4% | 1,028,242 |  | Added +722,020 |
| [ENLIVEN THERAPEUTICS INC (ELVN)](/companies/elvn.md) | COM | $7.6m | 0.4% | 150,000 |  | New +150,000 |
| [TARSUS PHARMACEUTICALS INC (TARS)](/companies/tars.md) | COM | $6.3m | 0.3% | 100,000 |  | Reduced −125,000 |
| [IBIO INC (IBIO)](/companies/ibio.md) | COM NEW | $6.2m | 0.3% | 3,570,000 |  | New +3,570,000 |
| CRINETICS PHARMACEUTICALS IN | COM | $4.7m | 0.2% | 125,000 |  | Reduced −125,000 |
| [ARCUTIS BIOTHERAPEUTICS INC (ARQT)](/companies/arqt.md) | COM | $4.6m | 0.2% | 175,000 |  | Reduced −275,000 |
| [ARROWHEAD PHARMACEUTICALS IN (ARWR)](/companies/arwr.md) | COM | $4.1m | 0.2% | 50,000 |  | Reduced −50,000 |
| [STRUCTURE THERAPEUTICS INC (GPCR)](/companies/gpcr.md) | SPONSORED ADS | $4.0m | 0.2% | 75,000 |  | Reduced −100,000 |
| RESEARCH ALLIANCE CORP III | ORD SHS CL A | $4.0m | 0.2% | 370,000 |  | New +370,000 |
| [COGENT BIOSCIENCES INC (COGT)](/companies/cogt.md) | COM | $3.9m | 0.2% | 100,000 |  | Reduced −100,000 |
| [ALTIMMUNE INC (ALT)](/companies/alt.md) | COM NEW | $3.8m | 0.2% | 1,250,000 |  | New +1,250,000 |
| [AMYLYX PHARMACEUTICALS INC (AMLX)](/companies/amlx.md) | COM | $3.6m | 0.2% | 200,000 |  | Reduced −150,000 |
| [ODYSSEY THERAPEUTICS INC (ODTX)](/companies/odtx.md) | COMMON STOCK | $3.3m | 0.2% | 175,000 |  | New +175,000 |
| [VAXCYTE INC (PCVX)](/companies/pcvx.md) | COM | $2.9m | 0.1% | 50,000 |  | Reduced −50,000 |
| [BOUNDLESS BIO INC (BOLD)](/companies/bold.md) | COM | $2.5m | 0.1% | 1,000,000 |  | New +1,000,000 |
| [QUINCE THERAPEUTICS INC (IRLA)](/companies/irla.md) | COM | $100.0k | <0.1% | 5,498 |  | New +5,498 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| ASCENDIS PHARMA A/S | SPONSORED ADR | $0 | 0.0% | 0 |  | Sold out −95,000 |
| [AXSOME THERAPEUTICS INC. (AXSM)](/companies/axsm.md) | COM | $0 | 0.0% | 0 |  | Sold out −50,000 |
| CENTESSA PHARMACEUTICALS PLC | SPONSORED ADS | $0 | 0.0% | 0 |  | Sold out −1,050,000 |
| [CONTEXT THERAPEUTICS INC (CNTX)](/companies/cntx.md) | COM | $0 | 0.0% | 0 |  | Sold out −529,550 |
| [MAZE THERAPEUTICS INC (MAZE)](/companies/maze.md) | COM | $0 | 0.0% | 0 |  | Sold out −750,000 |
| [MONTE ROSA THERAPEUTICS INC (GLUE)](/companies/glue.md) | COM | $0 | 0.0% | 0 |  | Sold out −400,000 |
| [OLEMA PHARMACEUTICALS INC (OLMA)](/companies/olma.md) | COM | $0 | 0.0% | 0 | Call | Sold out −500,000 |
| [RALLYBIO CORP (RLYB)](/companies/rlyb.md) | COM | $0 | 0.0% | 0 |  | Sold out −400,000 |
| TERNS PHARMACEUTICALS INC | COM | $0 | 0.0% | 0 |  | Sold out −300,000 |
| ZURA BIO LTD | CLASS A ORD SHS | $0 | 0.0% | 0 |  | Sold out −1,450,000 |

Source: SEC EDGAR, Form 13F-HR, accession 0001583977-26-000007. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.